Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 5, 2013, Pages 469-483

  Dekaban, Gregory A ^a   Hamilton, Amanda M ^a   Fink, Corby A ^a   Au, Bryan ^a   de Chickera, Sonali N ^a   Ribot, Emeline J ^a   Foster, Paula J ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANATOMICAL LOCATIONS; CANCER IMMUNOTHERAPY; CELL-BASED THERAPY; IRON OXIDE NANOPARTICLE; MIGRATION EFFICIENCY; NON-INVASIVE IMAGING; NONINVASIVE METHODS; TUMOR IMMUNOTHERAPY;

BODY FLUIDS; CELLS; NONINVASIVE MEDICAL PROCEDURES; TUMORS; VACCINES;

MAGNETIC RESONANCE IMAGING;

CANCER VACCINE; CONTRAST MEDIUM; FLUORINE; IRON OXIDE; NANOPARTICLE;

CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INTERACTION; CELL LABELING; CELL MATURATION; CELL MIGRATION; CELL THERAPY; CELL TRACKING; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LYMPH NODE; MEDICAL TECHNOLOGY; NANOEMULSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; T LYMPHOCYTE;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CONTRAST MEDIA; DENDRITIC CELLS; EMULSIONS; FERRIC COMPOUNDS; HUMANS; IMMUNOTHERAPY; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MICE; MONOCYTES; NEOPLASMS; TIME FACTORS;

EID: 84884815550     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1227     Document Type: Review

References (93)

1. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012, 9:193-199.
2. Dimberu PM, Leonhardt RM. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med 2011, 84:371-380.
3. McAfee JG, MacVittie TJ. The impact of recent advances in immunology and cancer therapy on nuclear medicine. Semin Nucl Med 2001, 31:342-349.
4. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006, 6:476-483.
5. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010, 234:199-212.
6. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997, 186:1213-1221.
7. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246.
8. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boermann OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, et al. Magnetic resonance tracking of dendritic cells in melenoma patients for monitoring of cellular therapy. Nat Biotechnol 2005, 23:1407-1413.
9. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
10. Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines 2012, 11:721-731.
11. Arens R. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors. Adv Immunol 2012, 114:217-243.
12. Smits ELJM, Anguille S, Cools N, Berneman ZN, Van Tendeloo VFI. Dendritic cell-based cancer Gene Therapy. Hum Gene Ther 2009, 20:1106-1118.
13. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011, 187:6130-6142.
14. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011, 6:e18801.
15. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013, 62:125-135.
16. Schuler G. Dendritic cells in cancer immunotherapy. Eur J Immunol 2010, 40:2123-2130.
17. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, et al. Prolonged survival of dendritic cell-based vaccinated melanoma patients correlates with tumor-specific delayed Type- IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 2009, 27:945-952.
18. Van Brussel I, Berneman ZN, Cools N. Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm 2012, 2012:690643.
19. Blocklet D, Toungouz M, Kiss R, Lambermont M, Velu T, Duriau D, Goldman M, Goldman S. 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 2003, 30:440-447.
20. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59:3340-3345.
21. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003, 63:12-17.
22. Martin-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003, 198:615-621.
23. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol 2006, 36:2544-2555.
24. Verdijk P, Aarnstzen EHJG, Kesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JFM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009, 15:2531-2540.
25. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol 2011, 8:677-688.
26. Baumjohann D, Lutz MB. Non-invasive imaging of dendritic cell migration in vivo. Immunobiology 2006, 211:587-597.
27. Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004, 2:27.
28. Horiguchi S, Matsuoka T, Okamoto Y, Sakurai D, Kobayashi K, Chazono H, Hanazawa T, Tanaka Y. Migration of tumor antigen-pulsed dendritic cells after mucosal administration in the human upper respiratory tract. J Clin Immunol 2007, 27:598-604.
29. Awasthi S, Awasthi V, Magee DM, Coalson JJ. Efficacy of antigen 2/proline-rich antigen cDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii. J Immunol 2005, 175:3900-3906.
30. Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, de Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 2010, 31:7070-7077.
31. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999, 6:1305-1312.
32. Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, Preat V. Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release 2007, 124:81-87.
33. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004, 17:484-499.
34. de Chickera S, Willert C, Noad J, Mallett C, Foster PJ, Dekaban GA. Cellular MRI as a sensitive, non-invasive modality suitable for detecting differences between the migratory efficiencies of different DC populations in vivo. Int Immunol 2012, 24:29-41.
35. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
36. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504.
37. Frank JA, Anderson SA, Kalsih H, Jordan EK, Lewis BK, Yocum GT, Arbab AS. Methods for magnetically labeling stem and other cells for detection by in vivo magnetic resonance imaging. Cytotherapy 2004, 6:621-625.
38. Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellowes V, Read EJ, Frank JA. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005, 18:553-559.
39. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity. Magn Reson Imaging 1988, 6:647-653.
40. Scheffler K, Lehnhardt S. Principles and applications of balanced SSFP techniques. Eur Radiol 2003, 13:2409-2418.
41. Heyn C, Bowen CV, Rutt BK, Foster PJ. Detection threshold of single SPIO-labeled cells with FIESTA. Magn Reson Med 2005, 53:312-320.
42. Ramadan SS, Heyn C, Mackenzie LT, Chambers AF, Rutt BK, Foster PJ. Ex-vivo cellular MRI with b-SSFP: quantitative benefits of 3T over 1.5T. MAGMA 2008, 21:251-259.
43. Mohammadi-Nejad AR, Hossein-Zadeh GA, Soltanian-Zadeh H. Quantitative evaluation of optimal imaging parameters for single-cell detection in MRI using simulation. Magn Reson Imaging 2010, 28:408-417.
44. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med 2005, 53:329-338.
45. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006, 55:23-29.
46. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to the lmph nodes. Cancer Res 2009, 69:3180-3187.
47. Dekaban GA, Snir J, Schrum B, De Chickera S, Willert C, Said EA, Sekaly RP, Foster PJ, O'Connell PJ. Semi-quantitation of mouse dendritic cell migration in vivo using cellular MRI. J Immunother 2009, 32:240-251.
48. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9:581-593.
49. Bulte JW. In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol 2009, 193:314-325.
50. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of Ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008, 52:907-915.
51. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Periera BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:386-393.
52. de Chickera SN, Snir JA, Willert C, Rohani R, Foley R, Foster PJ, Dekaban GA. Labelling dendritic cells with SPIO has implications for subsequent in vivo migration as assessed with cellular MRI. Contrast Media Mol Imaging 2011, 6:314-327.
53. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007, 243:467-474.
54. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003, 49:1006-1013.
55. Kobukai S, Baheza R, Cobb JG, Virostko J, Xie J, Gillman A, Koktysh D, Kerns D, Does M, Gore JC, et al. Magnetic nanoparticles for imaging dendritic cells. Magn Reson Med 2010, 63:1383-1390.
56. Kunzmann A, Andersson B, Vogt C, Feliu N, Ye F, Gabrielsson S, Toprak MS, Buerki-Thurnherr T, Laurent S, Vahter M, et al. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol 2011, 253:81-93.
57. Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, Yang JS, Kim S, Kim YK, Seong SY. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol 2011, 6:675-682.
58. Tachibana Y, Enmi J, Mahara A, Iida H, Yamaoka T. Design and characterization of a polymeric MRI contrast agent based on PVA for in vivo living-cell tracking. Contrast Media Mol Imaging 2010, 5:309-317.
59. Braun K, Dunsch L, Pipkorn R, Bock M, Baeuerle T, Yang S, Waldeck W, Wiessler M. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics. Int J Med Sci 2010, 7:136-146.
60. Tang AM, Ananta JS, Zhao H, Cisneros BT, Lam EY, Wong ST, Wilson LJ, Wong KK. Cellular uptake and imaging studies of gadolinium-loaded single-walled carbon nanotubes as MRI contrast agents. Contrast Media Mol Imaging 2011, 6:93-99.
61. Shapiro EM, Koretsky AP. Convertible manganese contrast for molecular and cellular MRI. Magn Reson Med 2008, 60:265-269.
62. Bonetto F, Srinivas M, Heerschap A, Mailliard R, Ahrens ET, Figdor CG, de Vries IJ. A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer 2011, 129:365-373.
63. Janjic JM, Srinivas M, Kadayakkara DK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc 2008, 130:2832-2841.
64. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, de Vries IJ. (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol 2010, 28:363-370.
65. Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med 2009, 62:747-753.
66. Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas 2010, 39:510-515.
67. Boehm-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T. In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One 2011, 6:e29040.
68. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005, 23:983-987.
69. Helfer BM, Balducci A, Nelson AD, Janjic JM, Gil RR, Kalinski P, de Vries IJ, Ahrens ET, Mailliard RB. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy 2010, 12:238-250.
70. Waiczies H, Lepore S, Janitzek N, Hagen U, Seifert F, Ittermann B, Purfurst B, Pezzutto A, Paul F, Niendorf T, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One 2011, 6:e21981.
71. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007, 58:725-734.
72. Weise G, Basse-Luesebrink TC, Wessig C, Jakob PM, Stoll G. In vivo imaging of inflammation in the peripheral nervous system by (19)F MRI. Exp Neurol 2011, 229:494-501.
73. Carpenter RL, Eger EI 2nd, Johnson BH, Unadkat JD, Sheiner LB. Pharmacokinetics of inhaled anesthetics in humans: measurements during and after the simultaneous administration of enflurane, halothane, isoflurane, methoxyflurane, and nitrous oxide. Anesth Analg 1986, 65:575-582.
74. Martelli C, Borelli M, Ottobrini L, Rainone V, Degrassi A, Russo M, Gianelli U, Bosari S, Fiorini C, Trabattoni D, et al. In vivo imaging of lymph node migration of MNP- and (111)In-labeled dendritic cells in a transgenic mouse model of breast cancer (MMTV-Ras). Mol Imaging Biol 2012, 14:183-196.
75. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005, 5:619-628.
76. Humbert JM, Halary F. Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther 2012, 12:127-136.
77. Zhang X, de Chickera SN, Willert C, Economopoulos V, Noad J, Rohani R, Wang AY, Levings MK, Scheid E, Foley R, et al. Cellular magnetic resonance imaging of monocyte-derived dendritic cell migration from healthy donors and cancer patients as assessed in a scid mouse model. Cytotherapy 2011, 13:1234-1248.
78. Reis e Sousa C, Yap G, Schulz O, Rogers N, Schito M, Aliberti J, Hieny S, Sher A. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity 1999, 11:637-647.
79. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117:1195-1203.
80. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapensberg ML. Final maturation of dendiritic cells in association with impaired responsiveness to IFN-γ and bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999, 162:3231-3236.
81. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat Immunol 2000, 1:311-316.
82. Rohani R, de Chickera SN, Willert C, Chen Y, Dekaban GA, Foster PJ. In vivo cellular MRI of imaging of dendritic cell migration using micrometer-sized iron oxide (MPIO) particles. Mol Imaging Biol 2011, 13:679-694.
83. Bonetto F, Srinivas M, Weigelin B, Cruz LJ, Heerschap A, Friedl P, Figdor CG, de Vries IJ. A large-scale (19)F MRI-based cell migration assay to optimize cell therapy. NMR Biomed 2012, 25:1095-1103.
84. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt MW, Lesterhuis WJ, Van Riel M, Punt CJ, et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 2013, 19:1525-1533.
85. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 2008, 180:2270-2275.
86. Balducci A, Helfer BM, Ahrens ET, O'Hanlon CF 3rd, Wesa AK. Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI). J Inflamm 2012, 9:24.
87. Mackay PS, Kremers GJ, Kobukai S, Cobb JG, Kuley A, Rosenthal SJ, Koktysh DS, Gore JC, Pham W. Multimodal imaging of dendritic cells using a novel hybrid magneto-optical nanoprobe. Nanomedicine 2011, 7:489-496.
88. Mou Y, Hou Y, Chen B, Hua Z, Zhang Y, Xie H, Xia G, Wang Z, Huang X, Han W, et al. In vivo migration of dendritic cells labeled with synthetic superparamagnetic iron oxide. Int J Nanomedicine 2011, 6:2633-2640.
89. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011, 17:5725-5735.
90. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005, 17:170-174.
91. Koido S, Homma S, Takahara A, Namiki Y, Komita H, Nagasaki E, Ito M, Nagatsuma K, Uchiyama K, Satoh K, et al. Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J Biomed Biotechnol 2011, 2011:910836.
92. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
93. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging 2012, 5:509-517.